

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Gender: **Female** | Birth year: **1946** | WHO: **0**

Tumor: **Colorectum (cecum) carcinoma** | Lesions: **Lung, Peritoneal** | Stage: **IV**

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Recent molecular results

NGS & MSI Panel (15-Jan-2023)

Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

Trial-relevant IHC results

PD-L1	Score < 50%
-------	-----------------------

Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Warnings
FOLFIRI	<u>PHASE-3-CRC</u>	
	PFS: 10.0 months (95% CI: 10.0-12.0) OS: 25.0 months (95% CI: 25.0-30.0)	

Phase 2/3+ trials in NL that are open and potentially eligible (0 trials)

Trial	Cohort	Molecular	Sites	Warnings
-------	--------	-----------	-------	----------

Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<u>KRAS-G12D-TRIAL</u>	<i>KRAS G12D</i>	<i>KRAS G12D</i>	<i>UMC Utrecht</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Molecular Details

NGS & MSI Panel (15-Jan-2023)

Biopsy location	Lung
Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

IHC results

Ki67	Positive, score 90%
PD-L1	Score < 50%

Molecular history

Event	Description	Date	Panel
KRAS G12D (Tier III)	Mutation (cancer-associated variant) Loss of function	VAF 0.2232%	
TMB		8.0	
MSI		Stable	

Efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence																
FOLFIRI	<p>PHASE-3-CRC</p> <p>Patient characteristics:</p> <table border="1"> <tr> <td>WHO/ECOG</td><td>0: 100, 1: 80, 2: 20, 3: 0, 4: 0</td></tr> <tr> <td>Primary tumor location</td><td>Left: 145, Both or unknown: 10, Right: 45</td></tr> <tr> <td>Mutations</td><td>KRAS exon 2 wild-type 200/200</td></tr> <tr> <td>Metastatic sites</td><td>Liver only: 58 (32.0%), Lung only: 10 (6.0%)</td></tr> <tr> <td>Previous systemic therapy</td><td>35/200</td></tr> <tr> <td>Prior therapies</td><td>Adjuvant chemotherapy</td></tr> <tr> <td>Median PFS:</td><td>10.0 months (95% CI: 10.0-12.0)</td></tr> <tr> <td>Median OS:</td><td>25.0 months (95% CI: 25.0-30.0)</td></tr> </table>	WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0	Primary tumor location	Left: 145, Both or unknown: 10, Right: 45	Mutations	KRAS exon 2 wild-type 200/200	Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)	Previous systemic therapy	35/200	Prior therapies	Adjuvant chemotherapy	Median PFS:	10.0 months (95% CI: 10.0-12.0)	Median OS:	25.0 months (95% CI: 25.0-30.0)
WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0																
Primary tumor location	Left: 145, Both or unknown: 10, Right: 45																
Mutations	KRAS exon 2 wild-type 200/200																
Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)																
Previous systemic therapy	35/200																
Prior therapies	Adjuvant chemotherapy																
Median PFS:	10.0 months (95% CI: 10.0-12.0)																
Median OS:	25.0 months (95% CI: 25.0-30.0)																

PHASE-3-CRC

Study: PHASE-3-CRC, Phase III, Adjuvant

Molecular requirements: None

Therapies: FOLFIRI+Cetuximab, FOLFIRI

Patient characteristics:

	Cetuximab + FOLFIRI (n=100)	FOLFIRI (n=200)
Age (median [range])	65.0 [40-75]	65.0 [30-75]
Sex	Male: 50	Male: 120

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

	Female: 50	Female: 80
Race	NA	NA
Region	Europe: 100 patients	Europe: 200 patients
WHO/ECOG	0: 80, 1: 10, 2: 10, 3: 0, 4: 0	0: 100, 1: 80, 2: 20, 3: 0, 4: 0
Primary tumor location	Left: 78 Both or unknown: 3 Right: 19	Left: 145 Both or unknown: 10 Right: 45
Mutations	KRAS exon 2 wild-type 100/100	KRAS exon 2 wild-type 200/200
Metastatic sites	Liver only: 62 (62.0%), Lung only: 4 (4.0%)	Liver only: 58 (32.0%), Lung only: 10 (6.0%)
Time of metastases	Unknown	Unknown
Previous systemic therapy	30/100	35/200
Prior therapies	Adjuvant chemotherapy	Adjuvant chemotherapy

Primary endpoints:

Cetuximab + FOLFIRI	FOLFIRI	Hazard ratio (HR) / Odds Ratio (OR)	P value
---------------------	---------	-------------------------------------	---------

Median follow-up for PFS was 70 months

Secondary endpoints:

Cetuximab + FOLFIRI	FOLFIRI	Hazard ratio (HR) / Odds Ratio (OR)	P value
---------------------	---------	-------------------------------------	---------


Median Overall Survival (95% CI)	35.0 (25.0 - 40.0)	25.0 months (25.0 - 30.0)	0.75 (0.6 - 0.95)	p = 0.011
Median Progression-Free Survival (95% CI)	10.0 (10.0 - 12.0)	10.0 months (10.0 - 12.0)	0.99 (0.8 - 1.25)	p = 1

Median follow-up for PFS was 70 months

ACTIN Report (research use only)


PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025





All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

SHAP values for treatment: No Treatment



SHAP values for treatment: FOLFIRI





Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

Treatment ranking

Event	Treatment	Score
8/14		

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

On label clinical evidence

Event	CKB Event	Level A	Level B	Level C	Level D
None					

Off label clinical evidence

Event	CKB Event	Level A	Level B	Level C	Level D
None					

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Clinical Details

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	None
Known allergies	Morphine
Recent surgeries	12-Nov-2021 Hemicolectomy right

Tumor details (05-Mar-2023)

Measurable disease	Yes
Known lesions	Lung, Peritoneal
Unknown lesions	Lymph node
No lesions present	CNS, Brain, Liver, Bone

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Trial Matching Details

National trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
KRAS-G12D-TRIAL	KRAS G12D	KRAS G12D	NL: Utrecht, Germany: Stuttgart

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).

International trials that are open and potentially eligible (0 trials)

Trial	Cohort	Molecular	Sites
-------	--------	-----------	-------

Trials and cohorts that are potentially eligible, but are closed (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
METC 01 IEMOEN	Applies to all cohorts below Dose escalation - monotherapy Dose expansion - monotherapy	None		Has not exhausted SOC

Trials and cohorts that are considered ineligible (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Applies to all cohorts below Dose expansion - monotherapy - Colorectum Dose expansion - monotherapy - NSCLC	KRAS G12D	PD-L1 expression below minimum of 50.0 No lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0 trials)

Trial	Cohort	Molecular	Sites	Configuration
None				

Other trials & cohorts

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

METC 02

Potentially eligible	No
Acronym	KAYRAS
Title	A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer
Reference	Evaluation
I-05	FAIL PD-L1 expression below minimum of 50.0

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes
Reference	Evaluation
I-02	FAIL No lung non-small cell carcinoma

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	B
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

METC 01

Potentially eligible	Yes
Acronym	IEMOEN
Title	Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Reference	Evaluation
I-03	WARN Has not exhausted SOC
E-01	PASS Has no other condition belonging to category autoimmune disease
E-02	PASS Hemoglobin above 6 mmol/L
E-03	PASS Neutrophils above 1.5
I-01	PASS Patient is at least 18 years old
I-02	PASS Has solid primary tumor Stage IV is considered metastatic

METC 01 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

13/14 Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

METC 01 - Dose expansion - monotherapy

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

14/14 Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).